AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$LQDA

Krepp Sarah sold $19K of LQDA

Krepp Sarah (Chief Human Resource Officer) sold 274 shares of Liquidia Corp (LQDA) at $67.76 on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Krepp Sarah
Published Sep 3, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 11:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The sale is modest and unlikely to move the stock.

02

Market read

Routine insider transaction with limited trading relevance.

03

What to watch

Potential upcoming clinical trial results or regulatory news not disclosed.

Relevance 2/10Novelty 3/10Timing: post-market 2026-09-01

Background

Form 4 filing provides the first public disclosure of the insider's sale.

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Chief Human Resource Officer sold 274 shares for $18,566 via a 10b5-1 plan on 2026-09-01.

Expected impact

No material move expected.

Evidence & confidence

The transaction size is trivial relative to total holdings and market cap.

Market effects

Sector

None significant for the biotech sector.

Regional

No regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

If the insider is reducing exposure, it could signal concerns about upcoming developments.

Key entities

  • Company
    Liquidia Corp

    Biopharmaceutical company listed on NASDAQ.

  • Insider
    Krepp Sarah

    Chief Human Resource Officer of Liquidia Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LQDA insider trading history →

Related articles

OCT 20
$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

news.alphastreet.com1 min
OCT 16
$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

biobuzz.io7 min
OCT 15
$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.

investing.com2 min